OMass Therapeutics announced a $310 million Series C funding round.
- Amount
- $310M
- Stage
- Series C
- Announced
- 16 October 2026
- Leads
- Bain Capital Life Sciences, Forbion, Novo Holdings
- Other investors
- Janus Henderson Investors, SV Health Investors, Jefferson Life Sciences, Syncona
- Use of funds
- Advance MC2 receptor antagonist OMS1620 through Phase 2 development, generate early clinical data, and attract top talent in the UK and US.
- Checked
- Amount and date matched across 2 press sources